Vera Therapeutics Poised for Strong Upside on 'Rare' Autoimmune Drug Opportunity, BofA Says

MT Newswires Live

Oct 17

Vera Therapeutics (VERA) offers a compelling entry point ahead of its anticipated mid-2026 commercial launch of atacicept, which could transform the treatment of immunoglobulin A nephropathy, BofA Securities said in a note Thursday.

BofA said atacicept's launch could exceed consensus estimates by 15% to 20% and ease competitive risk concerns as it launches into a multi billion dollar market.

Atacicept, designed to inhibit B-cell overactivity that drives autoimmune disorders, is being developed as a once weekly self-administered at-home injection.

BofA forecasts peak sales of about $3 billion by 2037, supported by potential label expansions and life-cycle management efforts that could extend its use to other rare kidney diseases.

The firm said Vera's pipeline of biologics targeting B-cell modulation, including MAU868 and VT-109, provide additional long-term upside in autoimmune disorders beyond immunoglobulin A nephropathy.

BofA initiated coverage of Vera Therapeutics with a buy rating and a $48 price target.

Price: 30.68, Change: -0.32, Percent Change: -1.03

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2576729301"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576729301\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576729301?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 00:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576729301","market":"fut","top_or_hot":-1,"title":"Vera Therapeutics Poised for Strong Upside on 'Rare' Autoimmune Drug Opportunity, BofA Says","media":"MT Newswires Live","content":"<html><body><p> Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VERA) offers a compelling entry point ahead of its anticipated mid-2026 commercial launch of atacicept, which could transform the treatment of immunoglobulin A nephropathy, BofA Securities said in a note Thursday.</p><p>BofA said atacicept's launch could exceed consensus estimates by 15% to 20% and ease competitive risk concerns as it launches into a multi billion dollar market.</p><p>Atacicept, designed to inhibit B-cell overactivity that drives autoimmune disorders, is being developed as a once weekly self-administered at-home injection.</p><p>BofA forecasts peak sales of about $3 billion by 2037, supported by potential label expansions and life-cycle management efforts that could extend its use to other rare kidney diseases.</p><p>The firm said Vera's pipeline of biologics targeting B-cell modulation, including MAU868 and VT-109, provide additional long-term upside in autoimmune disorders beyond immunoglobulin A nephropathy.</p><p>BofA initiated coverage of Vera Therapeutics with a buy rating and a $48 price target.</p><p>Price: 30.68, Change: -0.32, Percent Change: -1.03</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vera Therapeutics Poised for Strong Upside on 'Rare' Autoimmune Drug Opportunity, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVera Therapeutics Poised for Strong Upside on 'Rare' Autoimmune Drug Opportunity, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-17 00:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VERA) offers a compelling entry point ahead of its anticipated mid-2026 commercial launch of atacicept, which could transform the treatment of immunoglobulin A nephropathy, BofA Securities said in a note Thursday.</p><p>BofA said atacicept's launch could exceed consensus estimates by 15% to 20% and ease competitive risk concerns as it launches into a multi billion dollar market.</p><p>Atacicept, designed to inhibit B-cell overactivity that drives autoimmune disorders, is being developed as a once weekly self-administered at-home injection.</p><p>BofA forecasts peak sales of about $3 billion by 2037, supported by potential label expansions and life-cycle management efforts that could extend its use to other rare kidney diseases.</p><p>The firm said Vera's pipeline of biologics targeting B-cell modulation, including MAU868 and VT-109, provide additional long-term upside in autoimmune disorders beyond immunoglobulin A nephropathy.</p><p>BofA initiated coverage of Vera Therapeutics with a buy rating and a $48 price target.</p><p>Price: 30.68, Change: -0.32, Percent Change: -1.03</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2576729301","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576729301","pubTimestamp":1760633366,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vera Therapeutics  offers a compelling entry point ahead of its anticipated mid-2026 commercial launch of atacicept, which could transform the treatment of immunoglobulin A nephropathy, BofA Securities said in a note Thursday.BofA said atacicept's launch could exceed consensus estimates by 15% to 20% and ease competitive risk concerns as it launches into a multi billion dollar market.Atacicept, designed to inhibit B-cell overactivity that drives autoimmune disorders, is being developed as a once weekly self-administered at-home injection.BofA forecasts peak sales of about $3 billion by 2037, supported by potential label expansions and life-cycle management efforts that could extend its use to other rare kidney diseases.The firm said Vera's pipeline of biologics targeting B-cell modulation, including MAU868 and VT-109, provide additional long-term upside in autoimmune disorders beyond immunoglobulin A nephropathy.BofA initiated coverage of Vera Therapeutics with a buy rating and a $48 p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","VERA":"Vera Therapeutics, Inc.","BK4539":"次新股"},"translate_title":"美国银行表示，Vera Therapeutics有望在“罕见”的自身免疫药物机会中获得强劲上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERA":1.5},"content_text":"Vera Therapeutics (VERA) offers a compelling entry point ahead of its anticipated mid-2026 commercial launch of atacicept, which could transform the treatment of immunoglobulin A nephropathy, BofA Securities said in a note Thursday.BofA said atacicept's launch could exceed consensus estimates by 15% to 20% and ease competitive risk concerns as it launches into a multi billion dollar market.Atacicept, designed to inhibit B-cell overactivity that drives autoimmune disorders, is being developed as a once weekly self-administered at-home injection.BofA forecasts peak sales of about $3 billion by 2037, supported by potential label expansions and life-cycle management efforts that could extend its use to other rare kidney diseases.The firm said Vera's pipeline of biologics targeting B-cell modulation, including MAU868 and VT-109, provide additional long-term upside in autoimmune disorders beyond immunoglobulin A nephropathy.BofA initiated coverage of Vera Therapeutics with a buy rating and a $48 price target.Price: 30.68, Change: -0.32, Percent Change: -1.03","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}